Sensorion
Developing life-transforming therapies for patients with inner ear disorders involving vertigo and hearing loss.
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (24 %) | 74 % | 21 % | 18 % | - | - | (13 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (446 %) | (439 %) | (554 %) | (450 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (469 %) | (454 %) | (577 %) | (465 %) | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 401 % | 438 % | 570 % | 480 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Sensorion is a biopharmaceutical company founded in 2009, specializing in the development of therapies for debilitating inner ear disorders, such as hearing loss. The company operates in the healthcare and biotechnology markets, focusing on both clinical and preclinical stages of drug development. Sensorion's core clients include patients suffering from sudden sensorineural hearing loss and other inner ear conditions. The business model is centered around research and development, with revenue generated through the commercialization of its drug candidates and potential partnerships or licensing agreements. Sensorion has one clinical stage drug candidate for sudden sensorineural hearing loss and two preclinical gene therapy programs. The company also boasts a cutting-edge inner ear R&D platform, which underscores its commitment to scientific excellence and innovation.
Keywords: biopharmaceutical, inner ear disorders, hearing loss, gene therapy, clinical stage, preclinical, drug development, healthcare, biotechnology, R&D.